Vall d'Hebron Hospital Universitari

Running trials

• Not yet recruiting

  A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer

  2025-523599-21-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

  NCT07593040· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Trial of LAD603 in Patients with Systemic Lupus Erythematosus

  2026-527200-24-00· Phase 2· Almirall S.A.· Source

• Not yet recruiting

  Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)

  NCT07788664· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A research study to evaluate how well etavopivat works in children with sickle cell disease

  2025-524464-38-00· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

  NCT07858123· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Not yet recruiting

  A Phase 2 study of VQ-101 in participants with Parkinson’s disease and GBA1 mutation

  2026-525848-15-00· Phase 2· Vanqua Bio Inc.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions

  NCT07843797· Hospital Universitari Vall d'Hebron Research Institute· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Systimmune Inc.· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A Study of RO7871996 in Participants with Systemic Lupus Erythematosus

  2026-527221-35-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight

  2025-524616-11-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Pfizer· Source

• Recruiting

  Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)

  2025-523010-89-00· Phase 1/2· 35Pharma Inc.· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· Phase 2· Universitair Medisch Centrum Groningen· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

  2025-523374-17-03· Phase 4· Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca· Source

• Recruiting

  A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

  NCT07700758· Phase 2· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer

  2025-523276-23-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence

  2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source

• Recruiting

  AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational Study

  NCT07924371· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL

  2025-524915-36-00· Phase 1/2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Servier· Source

Showing 50 of 1233.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer130 recruiting
• Childhood cancers63 recruiting
• Colorectal cancer42 recruiting
• Ovarian cancer38 recruiting
• Metastatic breast cancer34 recruiting
• Pancreatic cancer34 recruiting
• Prostate cancer32 recruiting
• Gastric and oesophageal cancer31 recruiting
• Endometrial cancer24 recruiting
• Liver and biliary tract cancer22 recruiting
• Obesity21 recruiting
• Melanoma20 recruiting
• Acute myeloid leukaemia19 recruiting
• Bladder cancer19 recruiting
• Chronic lymphocytic leukaemia18 recruiting
• Stroke17 recruiting
• Triple-negative breast cancer17 recruiting
• Acute lymphoblastic leukaemia16 recruiting
• Head and neck cancer15 recruiting
• Kidney cancer15 recruiting
• Heart failure14 recruiting
• Multiple myeloma14 recruiting
• Hodgkin lymphoma12 recruiting
• Lupus (SLE)12 recruiting
• Sarcoma12 recruiting
• Diffuse large B-cell lymphoma11 recruiting
• Fatty liver disease (MASLD/MASH)11 recruiting
• Myelodysplastic syndromes11 recruiting
• Type 2 diabetes11 recruiting
• Follicular lymphoma10 recruiting
• Cervical cancer9 recruiting
• High blood pressure9 recruiting
• Neuroendocrine tumours9 recruiting
• Atrial fibrillation8 recruiting
• Bronchiectasis8 recruiting
• Chronic myeloid leukaemia8 recruiting
• Depression8 recruiting
• Mantle cell lymphoma8 recruiting
• Migraine8 recruiting
• Multiple sclerosis8 recruiting
• Myasthenia gravis8 recruiting
• Myeloproliferative neoplasms8 recruiting
• Chronic kidney disease7 recruiting
• Dermatomyositis and polymyositis (myositis)7 recruiting
• Haemophilia7 recruiting
• Idiopathic pulmonary fibrosis7 recruiting
• Immune thrombocytopenia (ITP)7 recruiting
• Parkinson disease7 recruiting
• Pulmonary arterial hypertension7 recruiting
• Rheumatoid arthritis7 recruiting
• Asthma6 recruiting
• Coronary artery disease6 recruiting
• Macular degeneration6 recruiting
• Narcolepsy6 recruiting
• Psoriatic arthritis6 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)5 recruiting
• Cystic fibrosis5 recruiting
• Duchenne muscular dystrophy5 recruiting
• IgA nephropathy5 recruiting
• Liver cirrhosis5 recruiting
• Neuroblastoma5 recruiting
• Sickle cell disease5 recruiting
• Dilated cardiomyopathy4 recruiting
• Epilepsy4 recruiting
• Irritable bowel syndrome4 recruiting
• Obstructive sleep apnoea4 recruiting
• Systemic sclerosis (scleroderma)4 recruiting
• Amyloidosis3 recruiting
• Graves' disease and hyperthyroidism3 recruiting
• Hidradenitis suppurativa3 recruiting
• HIV3 recruiting
• Osteoarthritis3 recruiting
• Primary biliary cholangitis3 recruiting
• Psoriasis3 recruiting
• Sjögren's disease3 recruiting
• Thyroid cancer3 recruiting
• Ankylosing spondylitis2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Bipolar disorder2 recruiting
• Brain aneurysm2 recruiting
• Coeliac disease2 recruiting
• Crohn's disease2 recruiting
• Cushing's syndrome2 recruiting
• Hepatitis B2 recruiting
• Myocarditis2 recruiting
• Thalassaemia2 recruiting
• Ulcerative colitis2 recruiting
• Alopecia areata1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• COPD1 recruiting
• Cytomegalovirus infection1 recruiting
• Diabetic eye disease1 recruiting
• Gaucher disease1 recruiting
• Glioblastoma1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Polycystic kidney disease1 recruiting
• Sarcoidosis1 recruiting
• Schizophrenia1 recruiting
• Tuberculosis1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A trial to learn how safe AZD9750 is and how well it works in people with metastatic prostate cancer when given with or without other anticancer drugs

  2024-516976-14-00· Phase 1/2· AstraZeneca AB· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

  2025-524038-24-00· Phase 3· Praxis Precision Medicines Inc.· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Merus B.V.· Source

• Recruiting

  A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01]

  NCT05607420· Phase 1/2· Cellectis· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Atavistik Bio Inc.· Source

• Completed

  A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms

  2025-520786-44-00· Phase 1/2· AstraZeneca AB· Source

• Completed

  A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

  NCT04892017· Phase 1/2· Deciphera Pharmaceuticals Inc.· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Biomx Ltd.· Source

• Completed

  A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer

  2024-519044-32-00· Phase 1/2· AstraZeneca AB· Source

• Completed

  A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

  2024-519651-28-00· Phase 1· CureVac SE· Source

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Citryll BV· Source

• Completed

  A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

  2024-519301-36-00· Phase 1· Boehringer Ingelheim International GmbH· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05896163· Phase 1/2· Pfizer Inc.· Source

• Completed

  A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

  2024-514745-10-00· Phase 1· Pfizer Inc.· Source

• Active, not recruiting

  Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)

  2024-517818-15-00· Phase 1/2· Merck Healthcare KGaA· Source

• Completed

  A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  NCT06685718· Phase 1· BeOne Medicines AG· Source

• Completed

  Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

  NCT06604858· Phase 2· MedSIR· Source

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Nuvig Therapeutics Inc.· Source

• Completed

  A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

  2024-517756-35-00· Phase 1· Pfizer Inc.· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs

  NCT06599502· Phase 1/2· AstraZeneca AB· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· BicycleTx Limited· Source

• Completed

  A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

  NCT06560645· Phase 1· Prelude Therapeutics Inc.· Source

• Completed

  Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial

  NCT06680622· Phase 2· Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH· Source

• Completed

  An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

  2024-517061-16-01· Phase 2· Praxis Precision Medicines Inc.· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

  NCT05846516· Phase 1· Boehringer Ingelheim International GmbH· Source

• Completed

  N/A

  2024-513121-22-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

  NCT05828303· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Active, not recruiting

  Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

  NCT06710132· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

  2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· AbbVie· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

  NCT07667322· Phase 1· Hoffmann-La Roche· Source

• Completed

  A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors

  2022-502367-37-00· Phase 1/2· Novartis Pharma AG· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source

• Completed

  A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

  2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source

• Active, not recruiting

  A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

  NCT06698042· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Janssen Cilag International· Source

Showing 50 of 573.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke166 works · 26 trials
• Lung cancer108 works · 337 trials
• Multiple sclerosis100 works · 32 trials
• Liver and biliary tract cancer84 works · 55 trials
• Colorectal cancer74 works · 104 trials
• Migraine54 works · 30 trials
• Kidney cancer40 works · 39 trials
• Bronchiectasis40 works · 12 trials
• Melanoma39 works · 62 trials
• Systemic sclerosis (scleroderma)38 works · 12 trials
• Sarcoma37 works · 36 trials
• Ovarian cancer35 works · 80 trials
• Metastatic breast cancer34 works · 98 trials
• Pancreatic cancer29 works · 70 trials
• Acute lymphoblastic leukaemia27 works · 28 trials
• Fatty liver disease (MASLD/MASH)24 works · 20 trials
• Crohn's disease24 works · 7 trials
• COPD24 works · 5 trials
• Congenital heart disease22 works · 1 trial
• Myelodysplastic syndromes22 works · 26 trials
• Endometrial cancer21 works · 44 trials
• Aortic aneurysm20 works · 1 trial
• Pulmonary arterial hypertension19 works · 17 trials
• Myeloproliferative neoplasms18 works · 16 trials
• Myocarditis18 works · 2 trials
• Neuroendocrine tumours17 works · 19 trials
• Hepatitis B16 works · 7 trials
• Cytomegalovirus infection16 works · 3 trials
• Neuroblastoma16 works · 10 trials
• Aortic stenosis15 works · 1 trial